Samsung Medical Center
Seoul, South Korea
NCT Number: NCT01470404
To assess the role of germline polymorphisms in xenobiotic metabolism genes in toxicity profile.
To assess the role of germline polymorphisms in genes associated with DNA repair, p53 tumor suppressor gene and angiogenesis pathway in predicting recurrence and survival in gastric cancer patients treated with adjuvant chemotherapy.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Seoul, South Korea
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: 36 months
Samsung Medical Center
Other
Pharmacogenomic Study to Predict Toxicity and Response in Gastric Cancer Patients Treated With Adjuvant Chemotherapy
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00342654
Digestive System Diseases, Digestive System Neoplasms
Beijing, China
View Trial DetailsNCT03399110
Digestive System Diseases, Digestive System Neoplasms
Guangzhou, China
View Trial DetailsNCT06904365
Anal Cancer, Anus Diseases
St Louis, Missouri, United States
View Trial DetailsNCT06384417
Breast Cancer, Breast Diseases
Hershey, Pennsylvania, United States
View Trial Details